In this video, Nancy U. Lin, MD, highlights practice-changing trials in the HER2-positive metastatic breast cancer space.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 ...

TOKYO & BASKING RIDGE, N.J., June 02, 2025--ENHERTU plus Pertuzumab Reduced Risk of Disease Progression or Death by 44% vs. THP as 1L Therapy in Patients w/ HER2 positive mBC in DESTINY-Breast09 ...

The breast cancer drug pertuzumab when added to Herceptin improved the treatment of women with early-stage, HER-2 positive breast cancer, researchers reported Friday at the annual meeting of the ...

Enhertu® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

Pertuzumab is a monoclonal antibody being studied in early-stage and metastatic HER2-positive breast cancer. It is an investigational HER2-targeted medicine called a HER2 dimerization inhibitor (HDI).

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy ...